Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Lung Cancer

Capmatinib for Lung Cancer Granted Breakthrough Therapy Designation

Posted on September 9, 2019
Post Views: 953

Lung CancerOfficials with the FDA have granted breakthrough therapy designation to Norvatis’ capmatinib therapy as an initial treatment for metastatic non-small cell lung cancer (NSCLC). Capmatinib is an oral investigational therapy. The research was presented by Dr. Fabrice Barlesi from Aix-Marseille University, France.

“We are pleased to announce that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to capmatinib (INC280) as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC),” said John Tsai, MD, Head of Global Drug Development and Chief Medical Officer, Novartis.

Novartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer. Treatments that receive Breakthrough Therapy Designation target a serious disease and demonstrate substantial improvement over existing therapies. The FDA granted Breakthrough Therapy Designation for capmatinib based on primary results from GEOMETRY mono-1 study presented at 2019 meeting of American Society of Clinical Oncology.

Novartis is a reimagining medicine that helps to extend the lives of people. Capmatinib is being investigated in a rare form of NSCLC and targets MET-signalling pathway, which is mutated in about 3 to 4% of all NSCLC cases. This mutation leads to tumors which in turn limit treatment options. Novartis revealed phase 2 results from its GEOMETRY mono-1 trial of capmatinib. The BTD process will see development and review of capmatinib expedited.

John Tsai, MD, head of global drug development and chief medical officer of Novartis, said in the release,“We look forward to working with the FDA and global health authorities to bring capmatinib to patients who currently have no available targeted therapy options.”

The information shared in this blog is for educational purposes only and is not a substitute for medical advice.

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,303)
  • Lung Cancer: Symptoms and Treatment (5,625)
  • What is Non-Small-Cell Lung Cancer? (5,531)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025
  • Lung Cancer Screening Is Beneficial For Non-Smokers As Well April 28, 2025
  • Understanding The Stage 0 Lung Cancer April 21, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
%d